医学
癌症
胃切除术
普通外科
前瞻性队列研究
腹腔镜检查
外科
内科学
作者
Qing Zhong,Dong Wu,Yiming Jiang,Qingliang He,Xueyi Dang,Dongbo Xu,Yuqin Sun,Guoqiang Su,Kaiqing Guo,Li‐Sheng Cai,Haoxiang Zhang,Wen Ye,Guang‐Tan Lin,Ping Li,Jian‐Wei Xie,Qi‐Yue Chen,Chao‐Hui Zheng,Jun Lü,Chang‐Ming Huang,Jian‐Xian Lin
标识
DOI:10.1097/js9.0000000000001388
摘要
Background: The efficacy of laparoscopic completion total gastrectomy (LCTG) for remnant gastric cancer (RGC) remains controversial. Methods: The primary outcome was postoperative morbidity within 30 days after surgery. Secondary outcomes included 3-year disease-free survival (DFS), 3-year overall survival (OS), and recurrence. Inverse probability treatment weighted (IPTW) was used to balance the baseline between LCTG and OCTG. Results: Final analysis included 46 patients with RGC who underwent LCTG at the FJMUUH between June 2016 and June 2020. The historical control group comprised of 160 patients who underwent open completion total gastrectomy (OCTG) in the six tertiary teaching hospitals from CRGC-01 study. After IPTW, no significant difference was observed between the LCTG and OCTG groups in terms of incidence (LCTG vs. OCTG: 28.0 vs. 35.0%, P =0.379) or severity of complications within 30 days after surgery. Compared with OCTG, LCTG resulted in better short-term outcomes and faster postoperative recovery. However, the textbook outcome rate was comparable between the two groups (45.9 vs. 32.8%, P =0.107). Additionally, the 3-year DFS and 3-year OS of LCTG were comparable to those of OCTG (DFS: log-rank P =0.173; OS: log-rank P =0.319). No significant differences in recurrence type, mean recurrence time, or 3-year cumulative hazard of recurrence were observed between the two groups (all P >0.05). Subgroup analyses and concurrent comparisons demonstrated similar trends. Conclusions: This prospective study suggested that LCTG was noninferior to OCTG in both short-term and long-term outcomes. In experienced centers, LCTG may be considered as a viable treatment option for RGC.
科研通智能强力驱动
Strongly Powered by AbleSci AI